Quick Answer
AbCellera Biologics Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $75.13 million for the year ending 2025.
- AbCellera Biologics Inc. showed an increase of +160.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from AbCellera Biologics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), AbCellera Biologics Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 547.0%.
- Historical annual values: Fiscal year 2025: $75.13 million | Fiscal year 2024: $28.83 million | Fiscal year 2023: $38.03 million | Fiscal year 2022: $485.42 million | Fiscal year 2021: $375.20 million | Fiscal year 2020: $233.16 million | Fiscal year 2019: $11.61 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: